
Weyerhaeuser - Lots...


| Price and Volume | |
|---|---|
| Recent Price | 31.43 |
| 52 Week High | 33.86 |
| 52 Week Low | 14.75 |
| Avg. Daily Vol. (Mil) | 0.18 |
| Beta (3 year) | 1.29 |
| Share Related Items | |
| Mkt Cap (Mil) | 635.98 |
| Shares Out (Mil) | 20.23 |
| Float (Mil) | 14.22 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 0.40 |
| Current Ratio | 0.50 |
| LT Debt/ Equity | 0.35 |
| Total Debt / Equity | 0.88 |
| Valuation Ratios | |
| Price Earnings | n.a. |
| Price/Sales | 17.00 |
| Price/Book | 20.79 |
| Price/Cash Flow | 215.00 |
| Per Share Data | |
| Earnings | 0.01 |
| Sales | 1.85 |
| Book Value | 1.51 |
| Cash Flow | 0.15 |
| Business Summary | |
|---|---|
| Ligand Pharmaceuticals, Inc., is a biotechnology company that operates with a business model focused on developing or acquiring assets. | |
| General Information | |
| 11119 North Torrey Pines Roa
Suite 200 La Jolla, CA 92037 |
|
| www.ligand.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 21 | |
| CEO: Mr. John L. Higgins | |
| Short Interest | |
| Current Month (Mil) | 2.00 |
| Previous Month (Mil) | 1.90 |
| Short Interest Ratio (Days) | 11.60 |
| Management Effectiveness | |
| Return on Equity | 0.30 |
| Return on Assets | 0.10 |
| Return on Investments | 0.20 |
| Profitability | |
| Gross Margin | 96.70 |
| EBIT Margin | 5.30 |
| Profit Margin | 0.30 |